AstraZeneca Fails to Soothe EU Ire Over Vaccine-Delivery Delays

The transcript discusses the European Union's growing frustration with Astra Zeneca over vaccine delivery delays. The EU, having invested €2.7 billion in vaccine development, is considering legal actions and potential export bans to ensure contracts are honored. The EU's health commissioner expressed unusual anger, emphasizing the need for transparency in vaccine production and distribution, as upfront payments were made to avoid such issues.

What is the main reason for the EU's frustration with AstraZeneca?

• Delays in vaccine deliveries despite EU's investment

• AstraZeneca's decision to stop vaccine production

• The EU's lack of investment in vaccine development

• AstraZeneca's refusal to sell vaccines to the EU

What actions is the EU considering to ensure vaccine contracts are respected?

• Reducing vaccine prices

• Negotiating new contracts

• Legal actions and export bans

• Increasing vaccine production

What does the EU want to ensure regarding vaccines produced in Europe?

• They are distributed equally worldwide

• They remain within the EU

• They are exported globally

• They are sold at a higher price

What is the EU's Health Commissioner emphasizing in her statement?

• The need for more vaccine production

• The expansion of vaccine exports

• The importance of transparency in vaccine distribution

• The reduction of vaccine prices

What concern does the EU have regarding their upfront payment for vaccines?

• It is being used for vaccines sent elsewhere

• It is not enough to cover costs

• It is causing financial strain

• It is leading to vaccine shortages